Spectrum of gynecologic malignancies in Northeastern Nigeria

Dauda A. Katagum[1*†], Uchenna S. Ezenkwa[2†],
Sunday E. Achanya[1†], Aliyu I. Lawan[3†], Dauda E. Suleiman[4†],
Mairo U. Kadaura[5†], Abba Kabir[6†], Adamu I. Adamu[7†],
Abubakar Kolomi Modu[8†], Hadiza Usman[9‡§],
Sophia H. L. George[10‡§], Matthew Schlumbrecht[10‡§]
and Bala M. Audu[1‡§]

[1]Department of Obstetrics and Gynecology, Federal University of Health Sciences/Federal Medical
Center, Azare, Nigeria, [2]Department of Histopathology, Federal University of Health Sciences/Federal
Medical Center Azare, Azare, Nigeria, [3]Department of Histopathology, College of Medical Sciences,
Gombe State University/Federal Teaching Hospital, Gombe, Nigeria, [4]Department of Histopathology,
College of Medical Sciences, Abubakar Tafawa Balewa University, Bauchi, Nigeria, [5]Department of
Clinical Microbiology, Federal University of Health Sciences, Azare, Nigeria, [6]Department of
Histopathology, College of Medical Sciences, University of Maiduguri/University of Maiduguri
Teaching Hospital, Maiduguri, Nigeria, [7]Department of Histopathology, Yobe State University/Yobe
State University Teaching Hospital, Damaturu, Nigeria, [8]Department of Pathology, Federal Medical
Center Nguru, Nguru, Nigeria, [9]Department of Obstetrics and Gynecology, Federal Medical Center
Nguru, Nguru, Nigeria, [10]Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic
Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine,
Miami, FL, United States

Background: The burden of female genital tract cancers in low—and middle-income countries (LIMC) is not yet well investigated. Although available studies are few, they are mainly based on single institutions. Here, four-year multi-institutional data on gynecologic cancers in northeastern Nigeria were examined to determine their distribution by age and subtype.

Patient and Methods: This is a cross-sectional descriptive study using available data on histologically diagnosed gynecologic cancers archived in the pathology departments and/or cancer registries of six tertiary hospitals in northeastern Nigeria over four years. Alongside tumor type (according to site), patient age and presenting complaints were also documented. Descriptive statistics were used to present categorical variables as proportions, while quantitative variables of age were presented as medians.

Results: A total of 863 gynecologic cancers were included in this study. The median age was 50 years (3 – 95 years) with a peak at 40 – 49 years. The uterine cervix was the most common site of cancer (66.6%, 575/863), while uterine corpus (15.5%, 134/863) and ovarian cancers (14.8%; 128/863) were nearly equal in proportion. Squamous cell cancer was the commonest histotype overall, while ovarian cancers had a preponderance of epithelial tumors in 67.9% (87/128) over sex cord stromal (12.5%; 16/128) and germ cell (9.4%, 12/128) tumors. The most common symptom was abnormal vaginal bleeding (38%) followed by abdominal swelling (21.1%) and foul-smelling vaginal discharge (14.1%). Population-based data also showed high parity among women in the region, ranging from 4 births to 7 births per woman in a reproductive lifetime (total fertility rate, TFR).

Conclusion: The spectrum of cancers of the female genital tract in this study mirrors the population demographics characterized by a high proportion of young women in their reproductive age. Efforts to reduce the burden of this disease are urgently warranted.

Introduction

Gynecological cancers (GC) are a significant public health concern globally. They affect the female reproductive system such as the vulva, vagina, cervix, uterus, fallopian tubes and ovaries. Recent global estimates report that about 1,473,427 new cases of GCs and 680,372 deaths occur annually (1). Risk factors vary depending on the type of cancer, and despite advancements in prevention, diagnosis and treatment, metastasis and recurrence remain a significant challenge in the disease control effort. Hence, early detection through screening and awareness of symptoms is crucial for improved outcomes (2).

Africa has the highest burden of GC, specifically, East Africa, with an age-standardized incidence rate (ASIR) of 50 per 100,000 person-years compared to the global rate of 30.3 per 100,000 person-years (1). Examining the component cancers reveals differences in predisposing factors. For example, cervical, vaginal and vulva cancers share in common an interplay between Human papillomavirus (HPV) infection and modifying lifestyle behaviors such as early age at sexual debut, multiple sexual partners, and cigarette smoking (3, 4). Multiparity, dietary habits and exposure to talcum powder are factors significantly associated with ovarian cancer, while hormonal influence and genetic predispositions contribute to endometrial cancer (5–7). These varying risk factors highlight the need for appropriate screening and diagnostic interventions at proper ages to prevent or treat the disease. Unfortunately, low- and middle-income countries (LMICs) continue to suffer from these cancers due to inadequate screening and treatment services in place to manage them.

GC affects women in diverse ways, either from the disease or its treatment. Changes in body image, sexual identity and perceived desirability, for instance, can strain social relations and ties (8). Also, fertility and reproductive functioning can be compromised, raising worries for the patient (9). These, in addition to the huge financial burden of care, can induce anxiety and depression in the patient (10)

Abbreviations: hrHPV, High risk Human papilloma virus; HPV, Human papilloma virus; HRT, Hormone replacement therapy; HDI, Human development index; FIGO, International Federation of Gynecology and Obstetrics (FIGO); GCT, Germ Cell tumors; CONSORT, Consolidated Standard of Reporting Trails; HIV - Human immunodeficiency virus.

To drive the needed policy towards reducing or eradicating the burden of GC in LMICs, credible epidemiological data reporting is pivotal. Nigeria, like other sub-Saharan African countries, is still grappling with a high burden of communicable diseases (11). However, accumulating evidence shows that incidence of NCDs are on the rise, even though poorly documented (12). Studies describing comprehensive aggregate national data on GC in the country are rare. Available data are single-institution based, often describing a single GC disease component (13–15). This underscores the need for a study to collectively document these diseases on a regional and nationwide level for effective policy formulation and interventional strategies.

The present study used multi-institutional data on GC to determine the disease burden in northeastern Nigeria. It highlighted existing gaps and proposed remedies to address care disparities in the region. The findings are hoped to be relevant to further discussions on GC care approaches in the region and similar populations elsewhere.

Patients and methods

A review of available histopathological data on gynecological cancers diagnosed over 4 years (January 2019 – December 2022) in tertiary hospitals within northeastern Nigeria was conducted retrospectively. The zone has six states – Adamawa, Bauchi, Borno, Gombe, Taraba and Yobe – with eight tertiary hospitals, Bauchi and Yobe having two each. Data retrieved included cancer organ or site, (uterine cervix, uterine corpus, fallopian tube, ovary, vagina, and vulva), patient age at diagnosis, and presenting complaints. All cases diagnosed within the study period were eligible for inclusion in the study, while all cases outside this range were excluded. Accrued data were reviewed by the pathologists in each of the contributing centers for conformity and reliability of information. When indicated, the histology slides were retrieved and examined using a light microscope to ascertain the proper classification of the cancer. Cases with doubtful classification and for which the slides were not available for review were further excluded. However, cases obtained from cancer registries were checked for accuracy of documentation as" cancer" and to ensure that they arose from the female reproductive tract. Otherwise, they were excluded.

The female population demographics for the geographical area were derived from the National Population Commission statistics report for 2020 (16). All required ethical and institutional approvals were obtained from the participating institutions. At the same time, the tumors were histologically classified based on the 5th Edition of the World Health Organization protocol on the classification of tumors of the female genital tracts (17). Fallopian tube cancers were classified together with ovarian cancers, as recommended by the International Federation of Gynecology and Obstetrics (FIGO) (18).

Patient data was deidentified before retrieval and analysis. Frequency statistics was used to categorize nominal and ordinal variables into proportions and percentages while the median age of patients was calculated using measures of central tendency (median) statistical tool. The results are presented as tables, figures and in textual formats.

Results

### Population of interest demographics in the Northeast zone

Six tertiary hospitals from four states in the region provided data for this study (Supplementary 1). These hospitals include the University of Maiduguri Teaching Hospital Borno State, Yobe State University Teaching Hospital, Yobe State, Federal Medical Center Nguru, Yobe State, Federal Teaching Hospital Gombe State, Federal Medical Center Azare, Bauchi State, and Abubakar Tafawa Balewa University Teaching Hospital, Bauchi State. Together, they serve a

population of about 22 million people, females making up about 49.4%. The population distribution of the states from which data were drawn is shown in Supplementary 2. Two landmark age groups are displayed: 0 -49 years representing birth, early childhood and reproductive age groups; while 50 - 80+ years encompasses the period of fertility decline, menopause, and older age characterized by hormone replacement use, and upsurge in the risk for those malignancies that are dependent on hormone and genetics as risk factors. Illustrated in Supplementary 3 is the Total Fertility Rate (TFR) for the women throughout their expected fertility years and describes a decline from the year 2008 through to the period under review (2019 – 2022). Borno state had the most decline followed by Yobe state while Bauchi state had the least reduction in fertility rate.

Cancer data by sites, age and histological variants

A total of 863 histologically confirmed GC were eligible for inclusion in the study. Stepwise exclusion of ineligible cases is shown in the CONSORT flowchart in Supplementary 4. Figure 1 illustrates the age distribution of the patients. The median age was 50 years (range 3 – 95 years), with peak incidence in the 5th decade followed by a second peak in the 7th decade. Figure 2 shows the various median ages of occurrence for the different cancer sites. Cervical cancer occurred at a higher age compared to ovarian and uterine corpus cancers, while cancers of the vagina and vulva had the least median age.

Table 1 shows the proportions and percentages of the various cancers observed in the study period. Cervical cancer was the most

FIGURE 1
Bar charts showing the age group distribution in decades of the study population.

FIGURE 2
Line graph portraying the trend of median ages of patients by cancer site.

common, followed by uterine cancers. A remarkable proportion of malignancies that occurred in the cervix were conveniently described as "others", as they included not only rare tumors such as sarcomas, non-Hodgkin lymphomas, and adenoid cystic carcinoma but also because some were not outrightly classified at the time of data storage. Corpus uteri malignancies were more of endometrioid carcinoma, followed closely by choriocarcinoma. Cases of endometrial stromal sarcoma and metastatic carcinomas to the uterus were also observed. Other histological subtypes are as outlined in Table 1.

Ovarian cancers in this study ranked third among the female genital malignancies. One case of fallopian tube cancer was seen, and this was a serous carcinoma. Together with the epithelial ovarian cancers, they constituted 67.9% (87/128) of the cancers. The various histologic variants of epithelial cancers were epithelial serous carcinoma, mucinous carcinoma, clear cell carcinoma, and endometroid carcinomas. Among the non-epithelial tumors which represented 27.3% (35/128) of all the ovarian cancers, 34.3% (12/35) were germ cell tumors (GCT), made up of immature teratoma, dysgerminoma, yolk sac tumor, choriocarcinoma and a cancer within a mature teratoma, while 45% (16/35) were of sex cord-stroma tumor in origin, all comprising of granulosa cell tumor. Few (6) cases among the ovarian cancer histotypes had no histological class designation. Thus, they could not be placed in any class. and were documented as "not available (NA)".

Vulvovaginal cancers accounted for 26 (3.0%) cases and were the least with predominance of squamous cell carcinoma (17 cases; 65.4%).

Gynecologic cancer presenting symptoms

The recorded history of presenting complaints was varied as there were sites with overlap in many cases. By organ sites, 87.5% and 91.7% of uterine and cervical cancer patients respectively complained of bleeding through the vagina, with coexisting foul-smelling vaginal discharge among the latter. Feeling of abdominal mass and swelling was seen among the ovarian cancer patients in

about 68% of cases, 10% of these had associated vaginal bleeding. Other symptoms included weight loss, body weakness, hemoptysis, chronic pelvic pain, leakage of fecal matter, miscarriage, protrusion par vagina, vaginal nodules, bleeding vulval mass and anorexia.

Discussion

This study has shown a remarkable burden of gynecologic malignancies that is predominantly driven by hrHPV infections (19). Our finding of more cervical cancer is similar to the study by Okunade et al. in southwest Nigeria but contrasts with a report of higher ovarian cancers in the southeast of Nigeria by Nzeribe et al. (14, 20) However, these two studies reported single tertiary institution data each, whilst the present study was multi-institutional and could represent a truer picture of the disease in the population studied. There was also a notable variation in the age of occurrence of cases among these study environments. Whereas the overall median age at diagnosis was 50 years in the present study with a peak at the 5th decade, Okunade et al. in contrast, found a mean age of 52 years with a peak at the 6th decade (20). These reports and that from the present study suggest that women in this population are likely to be diagnosed with gynecological cancer irrespective of subtype at a young age. Given the attendant impact of this on the economy and households, there is a need for interventions that will promote a demographic shift in the disease occurrence.

Besides low overall median age, variations were also observed among different cancer subtypes in this study. It was noted that while cervical cancer was diagnosed at a median age of 51 years, vulvovaginal cancers were diagnosed at a median age of 42 years. By histological subtype, the majority of these cancers were squamous cell carcinomas that are usually driven by a common aetiologic agent, the hrHPV (21–23). Other risk factors commonly associated with the development of these cancers, and which were likely present in this population going by the most recent census data, include high parity, early age at sexual debut, and multiple sexual

TABLE 1 The four broad groups of gynecologic cancers and their histological subtypes.

Organ site	Histologic subtypes	Frequency (N)	Percentage (%)
Uterine cervix	Squamous cell carcinoma	379	66
	Adenocarcinoma	58	10
	Others	138	24
Sub-Total		575	100
Uterine corpus	Choriocarcinoma	45	33.5
	Endometrioid carcinoma	48	35.8
	Squamous cell carcinoma	10	7.5
	Leiomyosarcoma	6	4.5
	Serous carcinoma	4	3.0
	Carcinosarcoma	4	3.0
	Others	17	12.7
Sub-Total		134	100
Ovary and fallopian tube	Epithelial cancers	87	68
	Sex cord stromal tumors	16	12.5
	Germ cell tumors	12	9.4
	Miscellaneous	7	5.5
	Subtype not available (NA)	6	4.6
Sub-Total		128	100
Vulvovaginal	Squamous cell carcinoma	17	65.4
	Adenocarcinoma	2	7.7
	Others	7	26.9
Sub-Total		26	100

partners (24–26). These cancer types also have premalignant stages that can be detected by screening and treated to forestall their transformation into a malignant disease (26). For example, vulvar intraepithelial neoplasia has two distinct subtypes, a usual type seen more in younger age groups and associated in over 80% of cases with HPV infection and a differentiated form that occurs in older women and is less HPV-dependent (27). Given the younger age of patients who had cervical, vaginal and vulval cancers in the present study, addressing issues surrounding HPV infection prevention, and early detection would help to reduce the burden of these malignancies in the region and perhaps the country at large as has been demonstrated in some Nordic countries (28). A population-specific approach may be needed in the African population as data suggests differences in hrHPV prevalence among the black population compared to White women (29).

Also, the absence of the cervix, as in women who had undergone a hysterectomy, should not preclude vaccination against hrHPV as studies have shown that they can develop lower genital tract HPV-associated cancers, such as vaginal, vulval and anal cancers in the future (30).

The finding of more epithelial cancer among ovarian cancers and at a young age in this study is in keeping with the literature (18). We suspect from the census data that the protective influence of high parity against ovarian cancers among women in this region could account for the overall low proportion of this group of malignant diseases in this study (31). Non-epithelial tumors, on the other hand, though still low in proportion, exceeded data documented in other studies (32). Whereas this may not represent an increase in incidence of cases, nevertheless, the age at diagnosis is in keeping with the age demographics reported by other studies (32).

Uterine cancer had similar incidence as ovarian cancer in this study, although it surpasses cervical and ovarian cancers in developed countries (19). Emerging evidence suggests that African American or Black women have both higher incidence and worse mortality from the disease than White women in the United States, suggesting racial disparity in disease occurrence that may be explained by differing genetic predispositions (33, 34). For example, Black women have been shown to have a much greater risk of high-grade (serous and carcinosarcoma) uterine cancers relative to White women. In the same cohort, copy-number high (serous-like) tumors had a direct correlation with percent African ancestry (35). Efforts to reduce the more readily modifiable risk factors of worse outcomes among Black women, such as low health education (including awareness of symptoms), late detection, treatment delays, and poor implementation of evidence-based treatment recommendations, should be prioritized to improve the women's health in this regard (36).

The high proportion of cases of gestational choriocarcinoma in this study raises significant concerns regarding the needs of the local population who develop these aggressive yet chemotherapy-sensitive pregnancy-related cancers, which could threaten their lives during their reproductive years. An explanation for this finding in this study is unclear. However, a review of literature on gestational choriocarcinoma across different regions globally showed that older maternal age, long-term oral contraceptive use and socioeconomic status were strong risk factors for this cancer subtype (37). While these risk factors have not been investigated presently, we recommend a high index of alertness by gynecologists to be able to salvage all such patients. Campaigns to encourage ante- and postnatal care services utilization are also expedient so that more women can be brought into the "safe net" of gynecologic care within which such adverse pregnancy outcomes can be detected and treated early.

The absence of data on tumor staging, treatment received and survival limits further analysis of the impact of the disease on the population. Recent studies from northern Nigeria revealed that about 67%-92% of women with GC present at a very advanced stage (38, 39). The region also suffers from a lack of skilled specialists for oncology care. Northeastern Nigeria has the lowest number of

obstetricians and gynecologists in the country (40). This has implications on whether the patients are diagnosed at all or on time. Indeed, it has been shown that about 80% of patients experience a delay in diagnosis within a hospital setting, which could be due to prolonged waiting time on account of high physician workload (38). Another area of concern is the availability of care and its accessibility. The predominant form of treatment fo GC in this region are surgery and chemotherapy, which the majority are not able to afford out-of-pocket (38, 39, 41). Radiation oncology services are rarer and have a very long waiting time (42). These care gaps warrant policy guidelines to address. Training of more manpower is urgently needed to detect cases early while strengthening GC care through infrastructural provision and universal health insurance coverage.

Other limitations to this study include the non-population level data reporting and incomplete classification of some cases according to sites of origin. Likewise, the non-inclusion of clinically diagnosed cases and non-documentation of the Human Immunodeficiency Virus infection status of the patients with cervical, vaginal and vulvar cancers, all affect accurate estimation of the burden and risk factors of the disease in the population. Future studies should be designed in such a way to capture these and determine the financial, social and psychological impact of the disease on the women and their families. This will help to determine how to support them along their care journey (43).

Conclusion

The spectrum of gynecologic cancers in this study reveals a need for HPV infection prevention through advocacy, vaccination, screening and treatment of premalignant lesions. While these will reduce the cases of cervical, vulva and vaginal cancers, health education to the women regarding possible symptoms and signs of endometrial and ovarian cancers will enable them to present early to hospital for care. Future research is required to determine the risk factors for endometrial and ovarian cancers in this population, alongside investigating the impact of GC on the women. Lastly, population-specific policy direction that takes into account required manpower and infrastructural need to curb GC morbidity and mortality is highly advocated.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Research Ethics and Review Committee, Federal Medical Center Azare. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

DK: Conceptualization, Methodology, Supervision, Writing – original draft, Writing – review & editing. UE: Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft. SA: Conceptualization, Data curation, Methodology, Writing – review & editing. AL: Conceptualization, Data curation, Methodology, Writing – original draft. DS: Conceptualization, Data curation, Methodology, Writing – original draft. MUK: Conceptualization, Methodology, Writing – review & editing. AK: Conceptualization, Data curation, Methodology, Writing – review & editing. AA: Conceptualization, Data curation, Methodology, Writing – review & editing. AKM: Conceptualization, Data curation, Methodology, Writing – review & editing. HU: Conceptualization, Data curation, Methodology, Writing – review & editing. SG: Conceptualization, Methodology, Supervision, Writing – review & editing. MS: Conceptualization, Methodology, Supervision, Writing – review & editing. BA: Conceptualization, Methodology, Supervision, Writing – review & editing.

Funding

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2025.1420113/full#supplementary-material

References

1. Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Anand MP, et al. Global burden of gynecological cancers in 2022 and projections to 2050. *J Glob Health*. (2024) 14:04155. Available online at: https://jogh.org/2024/jogh-14-04155 (Accessed February 4, 2025).

2. David D, Benjamin E. Gynecological cancers. *Indian J Contin Nurs Educ*. (2019) 20:46. Available online at: http://www.ijcne.org/text.asp?2019/20/1/46/268695 (Accessed February 4, 2025).

3. Zhang S, Xu H, Zhang L, Qiao Y, Department of Cancer Epidemiology and Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, et al. Cervical cancer: Epidemiology, risk factors and screening. *Chin J Cancer Res*. (2020) 32:720–8. doi: 10.21147/j.issn.1000-9604.2020.06.05?viewType=HTML

4. Kashyap N, Krishnan N, Kaur S, Ghai S. Risk factors of cervical cancer: A case-control study. *Asia-Pac J Oncol Nurs*. (2019) 6:308–14. Available online at: https://linkinghub.elsevier.com/retrieve/pii/S2347562521002687 (Accessed February 4, 2025).

5. Cramer DW, Vitonis AF, Terry KL, Welch WR, Titus LJ. The association between talc use and ovarian cancer: A retrospective case–control study in two US states. *Epidemiology*. (2016) 27:334–46. Available online at: http://journals.lww.com/00001648-201605000-00006 (Accessed February 15, 2025).

6. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health*. (2019) 11:287–99. Available online at: https://www.dovepress.com/ovarian-cancer-in-the-world-epidemiology-and-risk-factors-peer-reviewed-article-IJWH (Accessed 2/4/2025).

7. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: An umbrella review of the literature. *Int J Cancer*. (2019) 145:1719–30. doi: 10.1002/ijc.31961

8. Giacomoni C, Venturini E, Hoarau H, Guyon F, Conri V. How women with gynecological cancer deal with treatment: Issues of visibility and invisibility. *Gynécologie Obstétrique Fertil*. (2014) 42:795–9. Available online at: https://linkinghub.elsevier.com/retrieve/pii/S1297958914002811 (Accessed February 12, 2025).

9. Laganà AS, La Rosa VL, Rapisarda AMC, Platania A, Vitale SG. Psychological impact of fertility preservation techniques in women with gynecological cancer. *ecancermedicalscience*. (2017) 11. Available online at: http://www.ecancer.org/journal/editorial/62-psychological-impact-of-fertility-preservation-techniques-in-women-with-gynecological-cancer.php (Accessed February 14, 2025).

10. Yue X, Pruemer JM, Hincapie AL, Almalki ZS, Guo JJ. Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014. *J Gynecol Oncol*. (2020) 31:e52. doi: 10.3802/jgo.2020.31.e52

11. Muhammad F, Abdulkareem JH, Chowdhury AA. Major Public Health Problems in Nigeria: A review. *South East Asia J Public Health*. (2017) 7:6–11. Available online at: https://www.banglajol.info/index.php/SEAJPH/article/view/34672 (Accessed February 15, 2025).

12. Olukoya O. The war against non-communicable disease: how ready is Nigeria? *Ann Ib Postgrad Med*. (2017) 15:5–6.

13. Joseph A, Olisaemeka E, Rose A, Chukwudi O, Conrad E, Igwe N. Frequency and pattern of gynecological cancers in federal teaching hospital, Abakaliki, Nigeria. *J Basic Clin Reprod Sci*. (2015) 4:54. Available online at: http://www.jbcrs.org/text.asp?2015/4/2/54/161046 (Accessed December 16, 2023).

14. Nzeribe EA, Ododo NA, Eteike PO. Profile of gynecological cancers in a tertiary hospital, Eastern Nigeria. *Pan Afr Med J*. (2023) 44:9. doi: 10.11604/pamj.2023.44.139.39034

15. Usman A, Bello SS, Abdurrahman A, Rasheed FA, Adam S, Dahiru A. A histopathological review of gynecological Malignancies in Katsina state North-Western Nigeria. *ecancermedicalscience*. (2024) 18. Available online at: https://ecancer.org/en/journal/article/1750-a-histopathological-review-of-gynecological-malignancies-in-katsina-state-north-western-nigeria (Accessed February 15, 2025).

16. Oyetunji E. *National Population Commission Nigeria 2020*. Abuja, Nigeria: Nigeria Population Projection and Demographic Indicators-State and National. (2020).

17. World Health Organization. Female genital tumors. In: *WHO Classification of Tumors, 5th Edition* (2020).

18. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *Int J Gynecol Obstet*. (2021) 155:61–85. doi: 10.1002/ijgo.13878

19. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. (2021) 71:209–49. doi: 10.3322/caac.21660

20. Okunade KS, Ugwu AO, Soibi-Harry A, Rimi SG, Dawodu O, Ohazuruike EO, et al. Pattern of gynecological Malignancies iat a university teaching hospital in Southwest Nigeria: A 5-year review. *Niger Med J*. (2022) 63:127–32.

21. Kesic V, Carcopino X, Preti M, Vieira-Baptista P, Bevilacqua F, Bornstein J, et al. The European Society of Gynecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia. *Int J Gynecol Cancer*. (2023) 33:446–61. doi: 10.1136/ijgc-2022-004213

22. Baral SK, Biswas P, Kaium M, Islam M, Dey D, Saber MA, et al. A comprehensive discussion in vaginal cancer based on mechanisms, treatments, risk factors and prevention. *Front Oncol*. (2022) 12:883805/full. doi: 10.3389/fonc.2022.883805/full

23. Pedrão PG, Guimarães YM, Godoy LR, Possati-Resende JC, Bovo AC, Andrade CEMC, et al. Management of early-stage vulvar cancer. *Cancers*. (2022) 14:4184. Available online at: https://www.mdpi.com/2072-6694/14/17/4184 (Accessed December 16, 2023).

24. Brinton LA, Thistle JE, Liao LM, Trabert B. Epidemiology of vulvar neoplasia in the NIH-AARP Study. *Gynecol Oncol*. (2017) 145:298–304. Available online at: https://linkinghub.elsevier.com/retrieve/pii/S0090825817301518 (Accessed December 12, 2023).

25. Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. *Int J Gynecol Obstet*. (2021) 155:19–27. doi: 10.1002/ijgo.13867

26. Gardner CS, Sunil J, Klopp AH, Devine CE, Sagebiel T, Viswanathan C, et al. Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. *Br J Radiol*. (2015) 88:20150033. doi: 10.1259/bjr.20150033

27. Hoang LN, Park KJ, Soslow RA, Murali R. Squamous precursor lesions of the vulva: current classification and diagnostic challenges. *Pathol (Phila)*. (2016) 48:291–302. Available online at: https://linkinghub.elsevier.com/retrieve/pii/S0031302516339654 (Accessed December 16, 2023).

28. Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. *PloS One*. (2014) 9:e88323. doi: 10.1371/journal.pone.0088323

29. Jeudin P, Abebe T, Butler R, Hooi D, Watt A, Capo-chichi CD, et al. Human papilloma virus distribution across the African diaspora. *JCO Glob Oncol*. (2021) 7:1206–8. doi: 10.1200/GO.21.00151

30. Bogani G, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, Vercellini P, et al. HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of vaccination. *Tumori J*. (2024) 110:139–45. doi: 10.1177/03008916231208344

31. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. *Nat Rev Dis Primer*. (2016) 2:16061. Available online at: https://www.nature.com/articles/nrdp201661 (Accessed December 16, 2023).

32. Boussios S, Zarkavelis G, Seraj E, Zerdes I, Tatsi K, Pentheroudakis G. Non-epithelial ovarian cancer: elucidating uncommon gynecological Malignancies. *Anticancer Res*. (2016) 36:5031–42. Available online at: http://ar.iiarjournals.org/content/36/10/5031.abstract (Accessed December 16, 2023).

33. Kravchenko J, Akushevich I, Rhew SH, Agarwal P, Lyerly HK. Uterine cancer mortality in white and African American females in Southeastern North Carolina. *J Environ Public Health*. (2020) 2020:1–9. Available online at: https://www.hindawi.com/journals/jeph/2020/6734031/ (Accessed December 16, 2023).

34. Whetstone S, Burke W, Sheth SS, Brooks R, Cavens A, Huber-Keener K, et al. Health disparities in uterine cancer: report from the uterine cancer evidence review conference. *Obstet Gynecol*. (2022) 139:645–59. doi: 10.1097/AOG.0000000000004710

35. Sanchez-Covarrubias AP, Tabuyo-Martin AD, George S, Schlumbrecht M. African ancestry is associated with aggressive endometrial cancer. *Am J Obstet Gynecol*. (2023) 228:92–5.10. Available online at: https://linkinghub.elsevier.com/retrieve/pii/S0002937822005956 (Accessed December 24, 2023).

36. Schlumbrecht M, Wright K, George S. Unique considerations in early detection, risk, and awareness of endometrial cancer in black women. *Cancer Control*. (2023) 30:10732748231202952. doi: 10.1177/10732748231202952

37. Amalina MAF, Wang SM, al-Naggar RA, Thanikasalam K. Epidemiology of gestational choriocarcinoma: A systematic review. *OALib*. (2023) 10:1–11. Available online at: http://www.oalib.com/paper/pdf/6789492 (Accessed October 23, 2024).

38. Adamou N, Umar UA. Delayed presentation of patients with gynecological Malignancies in Kano, North-Western Nigeria. *Open J Obstet Gynecol*. (2015) 05:333–40. doi: 10.4236/ojog.2015.56048

39. Aminu MB, Ibrahim SM, Garba NA, Umar NI, Khan N, Usman HA. Gynecological Malignancies in Azare, North-East Nigeria: an assessment of types, stage at presentation and treatment affordability. *Int J Reprod Contracept Obstet Gynecol*. (2020) 9:1895. Available online at: https://www.ijrcog.org/index.php/ijrcog/article/view/8251 (Accessed February 16, 2025).

40. Agboghoroma CO, Gharoro EP. Coverage and distribution of obstetricians and gynecologists in Nigeria. *Int J Gynecol Obstet*. (2015) 129:50–3. doi: 10.1016/j.ijgo.2014.09.034

41. Oguntayo AO, Zayyan M, Akpar M, Kolawole AOD, Adewuyi SA. The burden of gynecological cancer management in Northern Nigeria. *Open J Obstet Gynecol*. (2013) 03:634–8. doi: 10.4236/ojog.2013.38115

42. Tumba N, Adeyemi Adewuyi S, Eguzo K, Adenipekun A, Oyesegun R. Radiotherapy waiting time in Northern Nigeria: experience from a resource-limited setting. *ecancermedicalscience*. 14. (2020) Available online at: https://ecancer.org/en/journal/article/1097-radiotherapy-waiting-time-in-northern-nigeria-experience-from-a-resourcelimited-setting (Accessed February 16, 2025).

43. Finocchario-Kessler S, Wexler C, Maloba M, Mabachi N, Ndikum-Moffor F, Bukusi E. Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective. *BMC Womens Health*. (2016) 16:29. Available online at: https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-016-0306-6 (Accessed December 16, 2023).